Clinical Trial Detail

NCT ID NCT01730118
Title Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

urinary bladder cancer

colon cancer

prostate cancer

Advanced Solid Tumor

renal cell carcinoma

Her2-receptor positive breast cancer

lung non-small cell carcinoma

ovarian cancer

Therapies

HER2 Vaccine

Age Groups: adult

Additional content available in CKB BOOST